Overview
MT-2 refers to Melanotan II, a synthetic cyclic alpha-MSH analog. It has measurable biologic activity, but activity alone does not establish a favorable risk–benefit profile for cosmetic tanning1,2.
Pigmentation is not evidence of protection against sunburn or skin cancer. The cited clinical literature does not justify increased ultraviolet exposure or replacing sunscreen and established sun-protection practices1,5.
Origin & development
The early pilot evaluated a lactam-bridged cyclic analog developed to stimulate melanogenesis. It included only 3 normal male volunteers, making it an exploratory observation rather than a broad safety assessment1.
Sexual-response observations led to further melanocortin research. Bremelanotide is related but is a distinct compound with a defined FDA-approved indication; approval of that drug does not extend to Melanotan II2,3.
Mechanism of action
Melanocortin-receptor stimulation can affect melanocytes and central neural circuits. The human literature demonstrates that pigmentation, yawning, nausea and sexual responses can appear together1,2.
A nonselective receptor profile helps explain the variety of effects. A cosmetic endpoint does not isolate exposure to the skin, and the cited studies cannot establish a safe route-specific therapeutic window for this preparation2,3,6.
- 1Activates melanocortin receptorsMelanotan II is a cyclic, non-selective melanocortin-receptor agonist, far more potent than natural α-MSH1,2.
- 2Stimulates melanin productionActing on melanocytes, it drives melanogenesis, producing increased pigmentation in the first human pilot1.
- 3Acts on central arousal circuitsThrough central melanocortin pathways, it triggered erections without sexual stimulation and increased reported desire in men with erectile dysfunction2.
- 4Engages wider physiologyMelanocortin receptors are found throughout the body, so nausea, flushing and fatigue are its most common side effects1,2.
- Melanocortin receptors
- MC1R pigmentation
- MC3R / MC4R
- Melanogenesis
- Central sexual-response pathways
Small human experiments
The pigmentation pilot was placebo-controlled but involved only 3 volunteers. Nausea and somnolence were observed, alongside pigmentation in some participants1.
A crossover report in 20 men described erectile responses in 17. Increased desire followed 68% of active doses versus 19% of placebo doses; these are dose-level observations in a small selected population, not response probabilities for all users2.
Visible pigmentation1
The first human pilot of Melanotan II documented increased skin pigmentation in healthy volunteers.
Erectile response2
In a placebo-controlled crossover, Melanotan II produced erections in 17 of 20 men with erectile dysfunction, without sexual stimulation.
Increased desire2
Men reported increased sexual desire after 68% of Melanotan II doses versus 19% of placebo doses.
From pharmacology to clinical questions
The pilot paper describes strong melanotropic activity in laboratory assays. That potency supported clinical investigation but cannot determine long-term cancer, cardiovascular or neurologic risk1.
The broader melanocortin mechanism is valuable scientifically, yet cosmetic use requires evidence about repeated systemic exposure. This dataset does not substitute animal receptor activity for that missing human risk assessment2,6.
Skin & systemic safety
Published reports include rhabdomyolysis with systemic toxicity and melanomas diagnosed in association with use. Case reports cannot establish causality or risk incidence, particularly where ultraviolet exposure and unregulated products are involved3,4,5.
New or changing moles warrant dermatology review. FDA also cites serious reports including priapism and neurologic syndromes; nausea, flushing, prolonged erections and systemic symptoms should never be dismissed as evidence that the product is working1,2,6.
- Nausea, flushing, fatigue and pigmentary changes can occur [1, 2, 6].
- Arrange dermatology monitoring and promptly assess new or changing moles [4, 5].
- Serious reports include systemic toxicity, rhabdomyolysis and priapism; incidence and causality are uncertain [3, 6].
- An erection lasting longer than expected or accompanied by pain requires urgent medical assessment.
- Not FDA-approved; tanning does not establish ultraviolet protection.
Supply, storage & administration
Early human work used subcutaneous injection; a nasal preparation should not be assumed to have equivalent absorption or a better safety profile1,2. Confirm the dispensed formulation, prescribed route and monitoring plan before use.
The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe7. Dosing is set by your provider.
Questions
MT-2 or PT-141?
PT-141 is bremelanotide, with an FDA-approved branded indication for a specific group of premenopausal women. Melanotan II has no such approval.
Does a darker tan replace sunscreen?
No. The cited studies do not establish protection from ultraviolet injury or skin cancer.
Does it cause melanoma?
Cases report an association, often with ultraviolet exposure. They do not establish causality or the magnitude of risk, but they justify taking skin changes seriously.
Why monitor moles?
Melanocortin stimulation can change pigmentation, and suspicious changes need assessment rather than attribution to the drug alone.
Are nasal products automatically safer?
No. Changing delivery does not establish purity, exposure, efficacy or safety.
References
- 1.Human study
Dorr RT, Lines R, Levine N, et al.. Life sciences, 1996. PMID 8637402
A controlled pigmentation pilot in 3 men observed pigmentation and adverse effects, including nausea and fatigue.
- 2.Human study
Wessells H, Levine N, Hadley ME, et al.. International journal of impotence research, 2000. PMID 11035391
Small crossover research in 20 men reported erections in 17 and increased desire after 68% of active versus 19% of placebo doses.
- 3.Human study
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. (opens in a new tab)
Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.), 2012. PMID 23121206
A confirmed-exposure case report described systemic toxicity, rhabdomyolysis and renal dysfunction.
- 4.Human study
Melanotan-associated melanoma. (opens in a new tab)
Paurobally D, Jason F, Dezfoulian B, et al.. The British journal of dermatology, 2011. PMID 21564053
A clinical report described melanoma occurring in association with melanotan use.
- 5.Human study
Melanoma associated with the use of melanotan-II. (opens in a new tab)
Hjuler KF, Lorentzen HF. Dermatology (Basel, Switzerland), 2014. PMID 24355990
A case report described melanoma after Melanotan II use combined with sunbed exposure.
- 6.Guidance / label
U.S. Food and Drug Administration. Regulatory guidance / prescribing information, 2026.
FDA describes limited human safety information and relevant compounding risks for Melanotan II.
- 7.Guidance / label
Preventing Unsafe Injection Practices (opens in a new tab)
Centers for Disease Control and Prevention. Regulatory guidance / prescribing information, 2024.
Use aseptic technique and a new sterile needle and syringe; opened multi-dose vials generally have a 28-day discard window unless the manufacturer specifies otherwise, never beyond original expiration.
Research summaries are educational and describe published studies, many in animal or cell models. They are not claims that this product treats any condition. Compounded medications are prepared by a licensed 503A pharmacy for individual patients and are not FDA-approved. Statements on this site have not been evaluated by the FDA. Products are dispensed only after review by a licensed provider. This site does not provide medical advice; talk to your provider before starting any therapy.